Immune Checkpoint Inhibitor–Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents

What are the distribution and characteristics of immune checkpoint inhibitor–induced diabetes (ICI-D) in patients across National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) trials?In this cohort study of 13 966 patients across 158 trials through an NCI-CTEP database, the overall cumulative incidence of ICI-D was low (0.52 per 100 treated patients), but incidence varied by treatment type and was lower if exposed to concurrent chemotherapy (0.26% with chemotherapy vs 0.65% without chemotherapy) and higher if exposed to combined immunotherapy (0.94% with combination immunotherapy vs 0.37% with programmed cell death 1 protein [PD-1] or programmed cell death 1 ligand 1 [PD-L1] monotherapy).Results of this report suggest that ICI-D risk varied significantly in different treatment settings.

Corresponding Author: Elad Sharon, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 (elad_sharon@dfci.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.